No Data
No Data
BioMarin Pharmaceutical Price Target Cut to $90.00/Share From $115.00 by Wells Fargo
Scotiabank Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Cuts Target Price to $78
Scotiabank analyst George Farmer maintains $Biomarin Pharmaceutical(BMRN.US)$ with a hold rating, and adjusts the target price from $95 to $78.According to TipRanks data, the analyst has a success
Stifel Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $87
Stifel analyst Paul Matteis maintains $Biomarin Pharmaceutical(BMRN.US)$ with a buy rating, and adjusts the target price from $115 to $87.According to TipRanks data, the analyst has a success rate
Evercore Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $115
Evercore analyst Cory Kasimov maintains $Biomarin Pharmaceutical(BMRN.US)$ with a buy rating, and maintains the target price at $115.According to TipRanks data, the analyst has a success rate of 56.7%
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $78 to $122
On Sep 17, major Wall Street analysts update their ratings for $Biomarin Pharmaceutical(BMRN.US)$, with price targets ranging from $78 to $122.Barclays analyst Gena Wang maintains with a buy rating,